Objective To systematically evaluate the clinical efficacy and safety of nimodipine combined with edaravone in the treatment of hypertensive intracerebral hemorrhage (HICH).Methods The databases of PubMed, Cochrane Database of System Reviews, EMbase, CNKI, VIP, Wanfang Data, and CBM were searched for randomized controlled trials (RCTs) on the efficacy of nimodipine combined with edaravone in the treatment of HICH, which strictly met the inclusion and exclusion criteria. And a meta-analysis was performed using software RevMan (version 5.1).Results A total of 8 RCTs involving 610 patients with HICH were evaluated. The meta-analysis showed that the overall response rate of the combination therapy group was significantly higher than that of the control group (OR=3.15, 95% CI: 2.06-4.83). After treatment, both groups showed significantly reduced neurologic impairment score and volumes of cephalophyma and brain edema (P<0.05), but the neurologic impairment score and volumes of cephalophyma and brain edema in the therapy group were significantly lower than those in the control group (P<0.05), and the volume of cephalophyma in the therapy group was significantly reduced compared with that in the control group (SMD=-5.14, 95% CI: -5.83-(-4.45)). Conclusions For patients with HICH, nimodipine combined with edaravone has significant clinical efficacy in the treatment of hypertensive cerebral hemorrhage, and can improve the functional rehabilitation of the nerves and effectively reduce the volumes of intracranial hematoma and peripheral edema.